These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 20953643)

  • 41. Contralateral Upper Limb Weakness Following Botulinum Toxin A Injection for Poststroke Spasticity.
    Camões-Barbosa A; Ribeiro IM; Medeiros L
    Acta Med Port; 2020 Nov; 33(11):761-764. PubMed ID: 31759399
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Lambert-Eaton Myasthenic Syndrome, Botulism, and Immune Checkpoint Inhibitor-Related Myasthenia Gravis.
    Guidon AC
    Continuum (Minneap Minn); 2019 Dec; 25(6):1785-1806. PubMed ID: 31794471
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Repetitive ocular vestibular evoked myogenic potentials in myasthenia gravis.
    de Meel RHP; Keene KR; Wirth MA; Weber KP; Badrising UA; Verschuuren JJ; Tannemaat MR
    Neurology; 2020 Apr; 94(16):e1693-e1701. PubMed ID: 32217778
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Sanders DB; Guptill JT
    Continuum (Minneap Minn); 2014 Oct; 20(5 Peripheral Nervous System Disorders):1413-25. PubMed ID: 25299290
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Repetitive nerve stimulation and single-fiber electromyography in the evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: Review of recent literature.
    Chiou-Tan FY; Gilchrist JM
    Muscle Nerve; 2015 Sep; 52(3):455-62. PubMed ID: 26109387
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acquired disorders of the neuromuscular junction.
    O'Neill GN
    Int Anesthesiol Clin; 2006; 44(2):107-21. PubMed ID: 16849959
    [No Abstract]   [Full Text] [Related]  

  • 47. Immunological evidence for the co-existence of the Lambert-Eaton myasthenic syndrome and myasthenia gravis in two patients.
    Newsom-Davis J; Leys K; Vincent A; Ferguson I; Modi G; Mills K
    J Neurol Neurosurg Psychiatry; 1991 May; 54(5):452-3. PubMed ID: 1650816
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Botulinum toxin type A therapy for cervical dystonia.
    Castelão M; Marques RE; Duarte GS; Rodrigues FB; Ferreira J; Sampaio C; Moore AP; Costa J
    Cochrane Database Syst Rev; 2017 Dec; 12(12):CD003633. PubMed ID: 29230798
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Spinal muscular atrophy with features of myasthenia gravis and Eaton-Lambert syndrome. A case report].
    Ono S; Kurisaki H
    Rinsho Shinkeigaku; 1988 May; 28(5):497-500. PubMed ID: 2850884
    [No Abstract]   [Full Text] [Related]  

  • 50. Decrement pattern in Lambert-Eaton myasthenic syndrome is different from myasthenia gravis.
    Baslo MB; Deymeer F; Serdaroglu P; Parman Y; Ozdemir C; Cuttini M
    Neuromuscul Disord; 2006 Jul; 16(7):454-8. PubMed ID: 16806929
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myasthenia gravis: lessons for the emergency physician.
    Smulowitz PB; Zeller J; Sanchez LD; Edlow JA
    Eur J Emerg Med; 2005 Dec; 12(6):324-6. PubMed ID: 16276268
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Myasthenia, from the internist's point of view].
    Eymard B
    Rev Med Interne; 2014 Jul; 35(7):421-9. PubMed ID: 24112993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Modelling the response to low-frequency repetitive nerve stimulation of myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Miralles F
    Med Biol Eng Comput; 2016 Nov; 54(11):1761-1778. PubMed ID: 27016366
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Maddison P; McConville J; Farrugia ME; Davies N; Rose M; Norwood F; Jungbluth H; Robb S; Hilton-Jones D
    J Neurol Neurosurg Psychiatry; 2011 Jun; 82(6):671-3. PubMed ID: 20392977
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ocular aspects of myasthenia gravis.
    Barton JJ; Fouladvand M
    Semin Neurol; 2000; 20(1):7-20. PubMed ID: 10874773
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dental management of patients with myasthenia gravis: a literature review.
    Yarom N; Barnea E; Nissan J; Gorsky M
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2005 Aug; 100(2):158-63. PubMed ID: 16037773
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Importance of neuromuscular "jitter" under stimulation in the diagnosis of myasthenia gravis].
    Durand MC; Goulon-Goeau C; Gajdos P
    Neurophysiol Clin; 1997 Dec; 27(6):471-82. PubMed ID: 9488971
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Therapy in myasthenia gravis and Lambert-Eaton myasthenic syndrome.
    Newsom-Davis J
    Semin Neurol; 2003 Jun; 23(2):191-8. PubMed ID: 12894384
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dysphagia in cervical dystonia patients receiving optimised botulinum toxin therapy: a single-center retrospective cohort study.
    Kutschenko A; Klietz M; Paracka L; Kollewe K; Schulte-Sutum A; Janssen T; Schrader C; Wegner F; Dressler D
    J Neural Transm (Vienna); 2020 Aug; 127(8):1161-1165. PubMed ID: 32588245
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cosmetic botulinum toxin type A induced ptosis presenting as myasthenia.
    Parikh R; Lavin PJ
    Ophthalmic Plast Reconstr Surg; 2011; 27(6):470. PubMed ID: 22072210
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.